Paper Details

  1. Home
  2. Paper Details

[Review [new antibiotics series I]: cefuroxime (author's transl)].

Author: NakagawaK

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Cefuroxime, a new injectable cephalosporin, was found to be effective in treating 826 patients with various infections. The drug was stable to various beta-lactamases and achieved satisfactory blood levels. Cefuroxime was also found to be superior to cefazolin in treating respiratory and urinary tract infections.
Paper Details　
Original Abstract of the Article :
Cefuroxime (CXM) is a new injectable cephalosporin stable against beta-lactamases. The results of preclinical and clinical studies so far carried out in Japan on cefuroxime are summarized in this paper. 1. CXM is stable to various kinds of beta-lactamases except the one produced by P. vulgaris GN 76...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/7045446

データ提供：米国国立医学図書館（NLM）

Cefuroxime: A New Injectable Cephalosporin with Beta-Lactamase Stability

The world of antibiotics is a vast desert, with researchers constantly seeking new weapons to combat bacterial infections. This review focuses on cefuroxime (CXM), a new injectable cephalosporin that exhibits stability against beta-lactamases. This is like finding a new and powerful weapon in the desert, capable of overcoming the defenses of bacterial invaders.

Cefuroxime's Activity Against Beta-Lactamase-Producing Bacteria

The study found that CXM was effective against a wide range of bacteria, including those resistant to conventional cephalosporins. This is like discovering a weapon that can pierce the armor of previously impenetrable foes. CXM's stability against beta-lactamases, which are enzymes produced by bacteria to resist antibiotics, is a significant advantage.

Clinical Efficacy and Safety of Cefuroxime

The clinical trials demonstrated that CXM was highly effective in treating respiratory and urinary tract infections, with a low incidence of side effects. This is like finding a weapon that is both effective and safe to use.

Dr. Camel's Conclusion

This review highlights the potential of cefuroxime as a new and effective antibiotic. Its stability against beta-lactamases makes it a valuable tool in the fight against bacterial infections. The discovery of CXM is like finding a new oasis in the desert, offering a source of relief and hope for patients battling infections.

Date :
  1. Date Completed 1982-08-14
  2. Date Revised 2016-11-16
Further Info :

Pubmed ID

7045446

DOI: Digital Object Identifier

7045446

Related Literature

Article Analysis
・Side Effects of cefuroxime
SNS
PICO Info
in preparation
Languages

Japanese

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.